Mahana Therapeutics

What Mahana Therapeutics does

Mahana Therapeutics is a US-based, privately held digital therapeutics company founded in 2018 and headquartered in San Francisco that develops prescription and over-the-counter software-based treatments for chronic gastrointestinal conditions. Its flagship product, Nerva, is a digital gut-brain therapy program that delivers evidence-based, gut-directed hypnotherapy through short daily sessions over a six-week curriculum, targeting gut-brain axis disorders including irritable bowel syndrome (IBS), functional dyspepsia, functional constipation, and functional heartburn. The program is co-founded by Dr. Simone Peters, whose Monash University clinical trial demonstrated efficacy comparable to the Low FODMAP diet for IBS, and is recommended in current clinical guidelines and referenced by 19,000+ clinicians. Mahana claims over 300,000 users with a 4.7/5 App Store rating across more than 30,000 reviews.

Mahana operates a direct-to-consumer subscription revenue model with a companion clinician referral channel and a nascent health-plan/organizational channel (via Mindset Health Labs), complemented in March 2024 by the acquisition of German remote monitoring firm HiDoc Technologies GmbH (also referenced as Cara Care), which added remote patient monitoring capabilities and a European commercial foothold. The company has raised approximately $81.6 million across a $12M Series A (January 2020), ~$8.6M extension (April 2020), and $61M Series B (August 2021) led by Jazz Venture Partners with Lux Capital, KKCG, Main Street Advisors, and Outsized Ventures. Mahana operates with 11–50 employees, holds SOC-2 Type 2 certification for data handling, and serves markets in the US, EU/Germany, and Australia.

Its core technology is a content- and protocol-driven digital therapeutic — not an AI-native platform — centered on scripted hypnotherapy audio, daily educational modules, and behavioral retraining; the HiDoc acquisition extends this into structured remote patient monitoring. Co-founders Simon Levy (CTO) and Robert Paull anchor the leadership team alongside VP of Finance Myla Puyat, though no broader management roster is disclosed. Pricing is not publicly disclosed, consistent with a hybrid DTC subscription and emerging payer-facing commercialization model.

Name

Mahana Therapeutics

Website

https://www.mahana.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Mahana Therapeutics is a San Francisco-based digital therapeutics company that develops the Nerva app — an evidence-based, gut-directed hypnotherapy program for IBS and related gut-brain disorders — serving over 300,000 consumers and 19,000+ referring clinicians across the US, EU, and Australia.

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Software Publishers (513210)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Prepackaged Software (7372)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industries

Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Digital therapeutics
• Gut-brain therapy
• Digestive health software
• IBS management program
• Chronic condition management

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Digital Therapeutics Commercialization: Mahana Therapeutics generates revenue through the commercialization of prescription and over-the-counter digital therapeutics targeting chronic conditions, primarily in the digestive health space.

Go-to-market motion1 record

Core offering

Mahana Therapeutics develops and sells digital therapeutics for gastrointestinal conditions, with its flagship Nerva program delivering an evidence-based, self-guided 6-week gut-brain therapy via mobile app. The company provides digital tools for individuals with IBS and related gut-brain disorders, and also extends its platform through clinician channels and healthcare organization partnerships, including remote patient monitoring capabilities acquired via HiDoc Technologies.

Product overview

Mahana Therapeutics is a US-based digital chronic condition management provider focused on digestive health. The company's primary product portfolio centers on Nerva, a digital gut-brain therapy program for gut-brain axis disorders such as IBS, along with HiDoc Technologies (acquired March 2024), a German remote monitoring platform that expanded Mahana's capabilities in remote patient monitoring for gastrointestinal conditions. Nerva operates as a self-guided digital program featuring gut-directed hypnotherapy techniques designed to retrain communication between the gut and brain, while HiDoc provides remote monitoring capabilities across US and European markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Nerva Evidence-based, self-guided 6-week digital gut-brain therapy program delivered via mobile app for adults with IBS and related functional gastrointestinal conditions; designed for at-home use without drugs or restrictive diets.
• HiDoc Technologies (Cara Care) Remote patient monitoring and digital GI care platform (also known as Cara Care) serving patients and healthcare providers managing digestive conditions; integrated into the Mahana portfolio following the March 2024 acquisition.

Quantifiable outcome

• Global digital therapeutics market projected to reach USD 100 billion by 2035 at 25.9% CAGR
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• HiDoc Technologies GmbHcoreStrategic or Co-development Partner · 1 March 2024In March 2024, Mahana Therapeutics acquired German remote monitoring firm HiDoc Technologies GmbH to expand its digestive health offerings and commercial reach across US and European markets. This acquisition provided Mahana with remote patient monitoring technology capabilities for gastrointestinal chronic conditions including IBS, GERD, and celiac disease.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Akili Interactive: Prescription digital therapeutic company developing software-based cognitive therapies. Closely comparable to Mahana as a regulated, evidence-based DTx company with clinician-referred prescription products.
• Click Therapeutics: Prescription digital therapeutics platform developing software as a drug for chronic conditions. Comparable to Mahana in DTx business model, prescription pathway focus, and pharma partnerships.
• Better Therapeutics: Prescription digital therapeutic company for cardiometabolic conditions. Comparable to Mahana as a condition-specific, prescription-grade DTx pursuing payer reimbursement and clinical evidence.
• Kaia Health: Digital therapeutics company for chronic pain and musculoskeletal conditions. Comparable to Mahana in delivering evidence-based, app-delivered behavioral therapies for chronic conditions with employer/payer channels.
• Headspace Health: Digital mental health platform combining therapy, coaching, and self-guided behavioral programs. Comparable to Mahana in applying digital behavioral therapy techniques to chronic conditions with a subscription model.
• Zemedy (Bold Health): Digital therapeutic specifically targeting IBS and gut-brain disorders. Directly comparable to Nerva in product focus, mechanism (digital CBT/hypnotherapy for IBS), and target patient population.
• Pear Therapeutics: Pioneering prescription digital therapeutics company (subsequently filed for bankruptcy in 2023). Highly comparable to Mahana in prescription DTx business model, though serves as a cautionary precedent on DTx commercial execution.

Broad incumbents

• Omada Health: Leading virtual chronic care platform covering diabetes, hypertension, and behavioral health. Comparable to Mahana as a chronic-condition digital health company, but with a broader portfolio and larger employer/payer footprint.
• Virta Health: Digital health company reversing chronic metabolic conditions (type 2 diabetes, obesity) through telehealth and remote monitoring. Comparable to Mahana in chronic-condition digital therapeutics with health plan and employer channels.

Emerging players

• Wysa: AI-driven mental health digital therapeutic with employer and health plan channels. Comparable to Mahana in digital behavioral therapy delivery, though focused on mental health rather than GI.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/mahanatx
• Facebookfacebook.com/mahanatherapeutics
• LinkedInlinkedin.com/company/mahana-therapeutics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mahana Therapeutics